Disclosures for "Antibiotic exposure and risk of Parkinson's disease in the United Kingdom: A case-control study")
-
Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. The institution of Dr. Pal has received research support from National Institutes of Health. The institution of Dr. Pal has received research support from Parkinson's Foundation.
-
Dr. Bennett has stock in Bristol Myers Squibb. Dr. Bennett has stock in Merck. Dr. Bennett has stock in Cigna. Dr. Bennett has stock in Organon.
-
Dr. Roy has nothing to disclose.
-
Dr. Nyandege has nothing to disclose.
-
Dr. Mouradian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll Biopharma. Dr. Mouradian has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Society for Experimental Neurotherapeutics. Dr. Mouradian has stock in Alnylam, Eli Lilly. The institution of Dr. Mouradian has received research support from NIH, Michael J. Fox Foundation for Parkinson's Research; American Parkinson Disease Association. Dr. Mouradian has received intellectual property interests from a discovery or technology relating to health care. Dr. Mouradian has a non-compensated relationship as a Board of Directors with ANA that is relevant to AAN interests or activities.
-
Dr. Gerhard has nothing to disclose.
-
Daniel Horton has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Childhood Arthritis and Rheumatology Research Alliance. Daniel Horton has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pharmacoepidemiology & Drug Safety. The institution of Daniel Horton has received research support from Danisco USA Inc. The institution of Daniel Horton has received research support from Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation. Daniel Horton has received personal compensation in the range of $0-$499 for serving as a Consultant with US Food & Drug Administration. Daniel Horton has received personal compensation in the range of $500-$4,999 for serving as a Guideline Development Team Member, Speaker with American College of Rheumatology.